New York Life Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

New York Life Investment Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$202K	Buy	+2,688	New	+$212K	﹤0.01%	781

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

New York Life Investment Management's IONS Position: Q1 2026 in Review

New York Life Investment Management opened a new position in Ionis Pharmaceuticals (IONS) in Q1 2026: 2,688 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #781 among its holdings.

494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

New York Life Investment Management held 2,688 shares of Ionis Pharmaceuticals worth $202K as of Q1 2026.
Ionis Pharmaceuticals was a new New York Life Investment Management position in Q1 2026.
Ionis Pharmaceuticals made up ﹤0.01% of New York Life Investment Management's portfolio in Q1 2026, its #781 holding.
494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on New York Life Investment Management's 13F filing for Q1 2026, filed 7 May 2026.